Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
A Phase 1b/2, open-label, multicenter study to determine the recommended phase 2 (RP2D) of
ABT-101in solid tumor and to explore the preliminary antitumor activities of ABT101 in
patients with HER 2 mutated non-small cell lung cancer (NSCLC)